Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits

Nephrology Dialysis Transplantation

Volumn 17, Issue 12, 2002, Pages 2081-2083

  van der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SERINE PROTEINASE;

ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN PURIFICATION; ARTICLE; BAYES THEOREM; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HUMAN; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY; SOLID; STANDARDIZATION; WEGENER GRANULOMATOSIS; EVALUATION; IMMUNOLOGY; PATHOPHYSIOLOGY; STANDARD; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; REFERENCE STANDARDS; VASCULITIS;

EID: 0036905040     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.12.2081     Document Type: Article

References (25)

1. Davies DJ, Maran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis and antineutrophil antibody: possible arbovirus aetiology? Br Med J 1982; 285: 606
2. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's Granulomatosis. Lancet 1985; 1: 425-429
3. Savage CO. ANCA-associated renal vasculitis. Kidney Int 2001; 60: 1614-1627
4. Hagen EC, Andrassy K, Csernok E et al. EEC/BCR group for ANCA Assays standardization. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. J Immunol Method 1993; 159: 1-16
5. Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of antineutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international co-operative study on the standardization of ANCA-assays. J Immunol Method 1996; 196: 1-15
6. Hagen EC, Daha MR, Hermans J et al. The diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies (ANCA) in idiopathic systemic vasculitis. Results of an international collaborative study. Kidney Int 1998; 53: 743-753
7. Wiik A. Anti-neutrophil cytoplasmic antibodies tests: which tests should be used in practice? Internal Med 2001; 40: 466-470
8. Westman WA, Selga D, Bygren P et al. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 1998; 53: 1230-1236
9. Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies in Wegener's granulomatosis, a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101: 227-232
10. Nowack R, Grab I, Flores-Suarèz LF et al. ANCA titres, even of IgG subclasses, and soluble CD 14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001; 16: 1631-1637
11. Gisslen K, Wieslander J, Westberg G et al. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay and long-term clinical course in vasculitis. J Intern Med 2002; 251: 129-135 12 Jennette JG, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
12. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic vasculitis. Q J Med 1994; 87: 671-678
13. Langford C. The diagnostic utility of C-ANCA in Wegener's granulomatosis. Cleveland Clinic J Med 1998; 65: 135-140
14. McLaren JS, Stimson RH, McRorie ER et al. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in routine clinical setting. Q J Med 2001; 94: 615-621
15. Cohen-Tervaert JW, Huitema MG, Hené RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711
16. Markey BA, Warren JS. Use of anti-neutrophil cytoplasmic antibody assay to distinguish between vasculitis disease activity and complications of cytotoxic therapy. Am J Clin Pathol 1994; 102: 589-594
17. Arranz O, Rar J, Rodriguez R et al. Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. Clin Nephrol 2001; 56: 295-301
18. Maguchi S, Takizawa M, Miyatake Y et al. Antineutrophil cytoplasmic antibody (C-ANCA) levels in relation to treatment of Wegener's granulomatosis. Nippon Jibiinkoka Gakkai Kaiho 1995; 98: 974-983
19. Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescent test. Am J Nephrol 1995; 15: 201-207
20. Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37: 596-597
21. Cohen P, Guillevin L, Baril L et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol 1995; 13: 193-198
22. De'Oliviera J, Gaskin G, Dash A et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-389
23. van Pesch V, Jadoul M, Lefèbre C et al. Clinical significance of antiproteinase 3 antibody positivity in C-ANCA positive patients. Clin Rheum 199; 18: 279-282
24. Kyndt X, Reumaux D, Bridoux F et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 199; 106: 527-533
25. Girard T, Mahr A, Noel LH et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology 2001; 40: 147-151